See more : Blue Line Protection Group, Inc. (BLPG) Income Statement Analysis – Financial Results
Complete financial analysis of Odonate Therapeutics, Inc. (ODT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Odonate Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Bahema Educação S.A. (BAHI3.SA) Income Statement Analysis – Financial Results
- Banco da Amazônia S.A. (BAZA3.SA) Income Statement Analysis – Financial Results
- thyssenkrupp nucera AG & Co. KGaA (NCH2.DE) Income Statement Analysis – Financial Results
- GMS Inc. (GMS) Income Statement Analysis – Financial Results
- Immobiliere Distri-Land NV (DISL.BR) Income Statement Analysis – Financial Results
Odonate Therapeutics, Inc. (ODT)
About Odonate Therapeutics, Inc.
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Metric | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
---|---|---|---|---|---|---|
Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Research & Development | 117.04M | 104.03M | 79.95M | 27.90M | 2.62M | 0.00 |
General & Administrative | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 10.39M | 10.90M | 10.82M | 4.84M | 463.00K | 158.00K |
Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -316.00K |
Operating Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | -158.00K |
Cost & Expenses | 127.43M | 114.93M | 90.76M | 32.74M | 3.09M | 158.00K |
Interest Income | 0.00 | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 445.00K | 381.00K | 350.00K | 20.00K | 22.82K | 0.00 |
EBITDA | -125.91M | -111.44M | -88.61M | -32.72M | -3.09M | -158.00K |
EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Operating Income | -127.43M | -114.93M | -90.76M | -32.74M | -3.09M | -158.00K |
Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Total Other Income/Expenses | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
Income Before Tax | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Income Tax Expense | 1.08M | 3.11M | 1.80M | 0.00 | 0.00 | 0.00 |
Net Income | -126.35M | -111.83M | -88.96M | -32.74M | -3.09M | -158.00K |
Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
EPS | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
EPS Diluted | -3.85 | -4.05 | -3.64 | -2.31 | -0.11 | -0.01 |
Weighted Avg Shares Out | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
Weighted Avg Shares Out (Dil) | 32.82M | 27.63M | 24.46M | 14.17M | 26.89M | 26.89M |
Odonate Therapeutics Inc (NASDAQ:ODT) Shares Purchased by Alliancebernstein L.P.
AQR Capital Management LLC Acquires New Stake in Odonate Therapeutics Inc (NASDAQ:ODT)
Renaissance Technologies LLC Sells 1,226 Shares of Odonate Therapeutics Inc (NASDAQ:ODT)
Credit Suisse AG Has $326,000 Stake in Odonate Therapeutics Inc (NASDAQ:ODT)
Franklin Resources Inc. Has $38.61 Million Stock Holdings in Odonate Therapeutics Inc (NASDAQ:ODT)
Odonate Therapeutics Inc (NASDAQ:ODT) Given Consensus Recommendation of "Hold" by Brokerages
Odonate Therapeutics Inc (NASDAQ:ODT) Sees Significant Decrease in Short Interest
Odonate Therapeutics Sees Hammer Chart Pattern: Time to Buy?
Polémicos menús escolares en Telepizza y Rodilla: «Tengo cuatro hijos y estoy en el paro, solo quiero darles de comer»
Solidaridad en tiempos de crisis: Puleva, Telepizza o Rodilla, contra el coronavirus
Source: https://incomestatements.info
Category: Stock Reports